Evidence map›Paper›PMID 39890889›Full record

ArticleScientific reports2025

Long-term maintenance of patient-specific characteristics in tumoroids from six cancer indications.

Colin D Paul, Chris Yankaskas, Pradip Shahi Thakuri, Brittany Balhouse, Shyanne Salen, Amber Bullock, Sylvia Beam, Anthony Chatman, Sybelle Djikeng, Xiaoyu Jenny Yang and 14 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Colin D Paul *Thermo Fisher Scientific, Frederick, MD, USA. colin.paul@thermofisher.com.
Chris Yankaskas *Thermo Fisher Scientific, Frederick, MD, USA.
Pradip Shahi Thakuri *Thermo Fisher Scientific, Frederick, MD, USA.
Brittany BalhouseThermo Fisher Scientific, Frederick, MD, USA.
Shyanne SalenThermo Fisher Scientific, Frederick, MD, USA.
Amber BullockThermo Fisher Scientific, Frederick, MD, USA.
Sylvia BeamThermo Fisher Scientific, Frederick, MD, USA.
Anthony ChatmanThermo Fisher Scientific, Frederick, MD, USA.
Sybelle DjikengThermo Fisher Scientific, Frederick, MD, USA.
Xiaoyu Jenny YangThermo Fisher Scientific, Carlsbad, CA, USA.
Garrett WongThermo Fisher Scientific, Carlsbad, CA, USA.
Isha DeyThermo Fisher Scientific, Bengaluru, Karnataka, India.
Spencer HolmesThermo Fisher Scientific, Frederick, MD, USA.
Abigail DockeyThermo Fisher Scientific, Frederick, MD, USA.
Lindsay Bailey-SteinitzThermo Fisher Scientific, Carlsbad, CA, USA.
Lina ZhengThermo Fisher Scientific, Carlsbad, CA, USA.
Weizhong LiThermo Fisher Scientific, Carlsbad, CA, USA.
Vivek ChandraThermo Fisher Scientific, Carlsbad, CA, USA.
Jakhan NguyenThermo Fisher Scientific, Carlsbad, CA, USA.
Jason SharpThermo Fisher Scientific, Carlsbad, CA, USA.
Erik WillemsThermo Fisher Scientific, Carlsbad, CA, USA.
Mark KennedyThermo Fisher Scientific, Frederick, MD, USA.
Matthew R DallasThermo Fisher Scientific, Frederick, MD, USA. matthew.dallas@thermofisher.com.
David KuningerThermo Fisher Scientific, Frederick, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumoroids, sometimes referred to as cancer organoids, are patient-derived cancer cells grown as 3D, self-organized multicellular structures that maintain key characteristics (e.g., genotype, gene expression levels) of the tumor from which they originated. These models have emerged as valuable tools for studying tumor biology, cytotoxicity, and response of patient-derived cells to cancer therapies. However, the establishment and maintenance of tumoroids has historically been challenging, labor intensive, and highly variable from lab to lab, hindering their widespread use. Here, we characterize the establishment and/or expansion of colorectal, lung, head and neck, breast, pancreas, and endometrial tumoroids using the standardized, serum-free Gibco OncoPro Tumoroid Culture Medium. Newly derived tumoroid lines (n = 20) were analyzed by targeted genomic profiling and RNA sequencing and were representative of tumor tissue samples. Tumoroid lines were stable for over 250 days in culture and freeze-thaw competent. Previously established tumoroid lines were also transitioned to OncoPro medium and exhibited, on average, similar growth rates and conserved donor-specific characteristics when compared to original media systems. Additionally, OncoPro medium was compatible with both embedded culture in extracellular matrix and growth in a suspension format for facile culture and scale up. An example application of these models for assessing the cytotoxicity of a natural killer cell line and primary natural killer cells over time and at various doses demonstrated the compatibility of these models with assays used in compound and cell therapy development. We anticipate that the standardization and versatility of this approach will have important benefits for basic cancer research, drug discovery, and personalized medicine and help make tumoroid models more accessible to the cancer research community.

Indexed as

NeoplasmsOrganoidsCell Culture TechniquesCell Line, TumorFemaleHumans

Identifiers

PMID39890889
PMCPMC11785764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.